{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T04:05:58Z","timestamp":1778126758993,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100011819","name":"Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-024-03005-z","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T06:02:05Z","timestamp":1708408925000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The effect of combination therapy with intravitreal bevacizumab and topical timolol\u2013dorzolamide eye drops on diabetic macular edema: a double-blind randomized controlled trial"],"prefix":"10.1007","volume":"44","author":[{"given":"Sahba","family":"Fekri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1266-5002","authenticated-orcid":false,"given":"Ali","family":"Rabiei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadid","family":"Hooshmandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1808-0443","authenticated-orcid":false,"given":"Hosein","family":"Nouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed-Hossein","family":"Abtahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"issue":"1","key":"3005_CR1","first-page":"28","volume":"7","author":"K Miller","year":"2018","unstructured":"Miller K, Fortun JA (2018) Diabetic macular edema: current understanding, pharmacologic treatment options, and developing therapies. The Asia-Pacific J Ophthalmol 7(1):28\u201335","journal-title":"The Asia-Pacific J Ophthalmol"},{"issue":"2","key":"3005_CR2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S2213-8587(16)30052-3","volume":"5","author":"GS Tan","year":"2017","unstructured":"Tan GS et al (2017) Diabetic macular oedema. Lancet Diabetes Endocrinol 5(2):143\u2013155","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3005_CR3","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2156273","volume":"2016","author":"P Romero-Aroca","year":"2016","unstructured":"Romero-Aroca P et al (2016) Diabetic macular edema pathophysiology: vasogenic versus inflammatory. J Diabetes Res 2016:2156273","journal-title":"J Diabetes Res"},{"issue":"10","key":"3005_CR4","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.ophtha.2018.04.007","volume":"125","author":"TY Wong","year":"2018","unstructured":"Wong TY et al (2018) Guidelines on diabetic eye care: the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. Ophthalmology 125(10):1608\u20131622","journal-title":"Ophthalmology"},{"issue":"4","key":"3005_CR5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000458539","volume":"237","author":"U Schmidt-Erfurth","year":"2017","unstructured":"Schmidt-Erfurth U et al (2017) Guidelines for the management of diabetic macular edema by the european society of retina specialists (EURETINA). Ophthalmologica 237(4):185\u2013222","journal-title":"Ophthalmologica"},{"issue":"5","key":"3005_CR6","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri SJ et al (2007) Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114(5):855\u2013859","journal-title":"Ophthalmology"},{"issue":"4","key":"3005_CR7","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.ajo.2008.05.036","volume":"146","author":"TU Krohne","year":"2008","unstructured":"Krohne TU et al (2008) Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 146(4):508\u2013512","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"3005_CR8","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00417-013-2495-0","volume":"252","author":"E Moisseiev","year":"2014","unstructured":"Moisseiev E et al (2014) Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes. Graefes Arch Clin Exp Ophthalmol 252(2):331\u2013337","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"3005_CR9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1001\/jamaophthalmol.2016.0045","volume":"134","author":"J Sridhar","year":"2016","unstructured":"Sridhar J et al (2016) Topical dorzolamide\u2013timolol with intravitreous anti-vascular endothelial growth factor for neovascular age-related macular degeneration. JAMA ophthalmology 134(4):437\u2013443","journal-title":"JAMA ophthalmology"},{"issue":"2","key":"3005_CR10","first-page":"142","volume":"40","author":"H Terashima","year":"1996","unstructured":"Terashima H et al (1996) Membrane-bound carbonic anhydrase activity in the rat corneal endothelium and retina. Jpn J Ophthalmol 40(2):142\u2013153","journal-title":"Jpn J Ophthalmol"},{"key":"3005_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.preteyeres.2014.06.001","volume":"42","author":"G Casini","year":"2014","unstructured":"Casini G et al (2014) The \u03b2-adrenergic system as a possible new target for pharmacologic treatment of neovascular retinal diseases. Prog Retin Eye Res 42:103\u2013129","journal-title":"Prog Retin Eye Res"},{"issue":"6","key":"3005_CR12","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1111\/j.1471-4159.2011.07530.x","volume":"119","author":"D Martini","year":"2011","unstructured":"Martini D et al (2011) Antiangiogenic effects of \u03b22-adrenergic receptor blockade in a mouse model of oxygen-induced retinopathy. J Neurochem 119(6):1317\u20131329","journal-title":"J Neurochem"},{"issue":"1","key":"3005_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00417-008-0917-1","volume":"247","author":"SH Byeon","year":"2009","unstructured":"Byeon SH et al (2009) Prolongation of activity of single intravitreal bevacizumab by adjuvant topical aqueous depressant (Timolol\u2013Dorzolamide). Graefes Arch Clin Exp Ophthalmol 247(1):35\u201342","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"3005_CR14","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.oret.2019.01.017","volume":"3","author":"KG Falavarjani","year":"2019","unstructured":"Falavarjani KG et al (2019) Efficacy of topical timolol eye drops for the treatment of diabetic macular edema. Ophthalmol Retina 3(6):538\u2013539","journal-title":"Ophthalmol Retina"},{"issue":"2","key":"3005_CR15","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.joco.2019.01.008","volume":"31","author":"A Mirshahi","year":"2019","unstructured":"Mirshahi A et al (2019) Efficacy of adjuvant topical timolol\u2013dorzolamide with intravitreal bevacizumab injection in diabetic macular edema: a contralateral eye study. J Curr Ophthalmol 31(2):168\u2013171","journal-title":"J Curr Ophthalmol"},{"key":"3005_CR16","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/6794391","volume":"2020","author":"F Fazel","year":"2020","unstructured":"Fazel F, Nikpour H, Pourazizi M (2020) Combination of intravitreal bevacizumab and topical dorzolamide versus intravitreal bevacizumab alone for diabetic macular edema: a randomized contralateral clinical trial. Biomed Res Int 2020:6794391","journal-title":"Biomed Res Int"},{"key":"3005_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c332","volume":"340","author":"KF Schulz","year":"2010","unstructured":"Schulz KF et al (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 340:c332","journal-title":"BMJ"},{"issue":"2","key":"3005_CR18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0161-6420(99)00044-5","volume":"107","author":"RF Brubaker","year":"2000","unstructured":"Brubaker RF et al (2000) Comparison of the efficacy of betaxolol\u2013brinzolamide and timolol\u2013dorzolamide as suppressors of aqueous humor flow in human subjects. Ophthalmology 107(2):283\u2013287","journal-title":"Ophthalmology"},{"issue":"9","key":"3005_CR19","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.18240\/ijo.2021.09.18","volume":"14","author":"AE Badawi","year":"2021","unstructured":"Badawi AE et al (2021) Efficacy of topical dorzolamide 2% in diabetic cystoid macular edema. Int J Ophthalmol 14(9):1413\u20131418","journal-title":"Int J Ophthalmol"},{"key":"3005_CR20","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2147\/OPTH.S42188","volume":"7","author":"T Suzuki","year":"2013","unstructured":"Suzuki T et al (2013) Topical dorzolamide for macular edema in the early phase after vitrectomy and epiretinal membrane removal. Clin Ophthalmol 7:549\u2013553","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"3005_CR21","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nm1534","volume":"13","author":"BB Gao","year":"2007","unstructured":"Gao BB et al (2007) Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med 13(2):181\u2013188","journal-title":"Nat Med"},{"issue":"3","key":"3005_CR22","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.bbrc.2009.10.031","volume":"390","author":"Z Weiwei","year":"2009","unstructured":"Weiwei Z, Hu R (2009) Targeting carbonic anhydrase to treat diabetic retinopathy: emerging evidences and encouraging results. Biochem Biophys Res Commun 390(3):368\u2013371","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"3005_CR23","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000265251","volume":"15","author":"K Watanabe","year":"1983","unstructured":"Watanabe K, Chiou G (1983) Action mechanism of timolol to lower the intraocular pressure in rabbits. Ophthalmic Res 15(3):160\u2013167","journal-title":"Ophthalmic Res"},{"issue":"9","key":"3005_CR24","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1097\/IAE.0b013e318158ea28","volume":"27","author":"MW Stewart","year":"2007","unstructured":"Stewart MW (2007) Predicted biologic activity of intravitreal bevacizumab. Retina 27(9):1196\u20131200","journal-title":"Retina"},{"issue":"1","key":"3005_CR25","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1167\/iovs.16-20204","volume":"58","author":"JA Lavine","year":"2017","unstructured":"Lavine JA et al (2017) beta2-Adrenergic receptor antagonism attenuates CNV through inhibition of VEGF and IL-6 expression. Invest Ophthalmol Vis Sci 58(1):299\u2013308","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"3005_CR26","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/IAE.0000000000002293","volume":"39","author":"JH Lee","year":"2019","unstructured":"Lee JH et al (2019) Efficacy of adjuvant topical dorzolamide\u2013timolol in patients with neovascular age-related macular degeneration refractory to anti-vascular endothelial growth factor therapy. Retina 39(10):1953\u20131958","journal-title":"Retina"},{"issue":"5","key":"3005_CR27","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1001\/jamaophthalmol.2020.0724","volume":"138","author":"J Hsu","year":"2020","unstructured":"Hsu J et al (2020) Effect of adjuvant topical dorzolamide\u2013timolol vs placebo in neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmol 138(5):560\u2013567","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"3005_CR28","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/ICB.0000000000000752","volume":"15","author":"A Obeid","year":"2021","unstructured":"Obeid A et al (2021) Topical dorzolamide\u2013timolol with intravitreous anti-vascular endothelial growth factor for retinal vein occlusion: a pilot study. Retin Cases Brief Rep 15(2):120\u2013126","journal-title":"Retin Cases Brief Rep"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-024-03005-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-024-03005-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-024-03005-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T15:46:12Z","timestamp":1741880772000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-024-03005-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3005"],"URL":"https:\/\/doi.org\/10.1007\/s10792-024-03005-z","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,20]]},"assertion":[{"value":"13 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The Ethics Committee of Shahid Beheshti University of Medical Sciences approved the protocol of this study (ethics committee reference number: IR.SBMU.MSP.REC.1400.160).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients signed informed consent letters for participating in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All patients signed informed consent letters regarding the publication of their anonymized data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"101"}}